Drug Profile
HIV T-cell therapy - Fresenius
Latest Information Update: 18 May 2011
Price :
$50
*
At a glance
- Originator Fresenius AG
- Developer Fresenius SE & Co
- Class Cell therapies; Gene therapies; Small interfering RNA
- Mechanism of Action HIV fusion inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 14 Mar 2005 Data presented at the 12th Conference on Retroviruses and Opportunistic Infections (CROI-2005) have been added to the Viral Infections pharmacodynamics section
- 31 Jan 2004 Phase-I/II clinical trials in HIV infections treatment in Germany (Infusion)
- 19 Jan 2004 Preclinical trials in HIV infections treatment in Germany (Infusion)